Effects of viral strain, transgene position, and target cell type on replication kinetics, genomic stability, and transgene expression of replication-competent murine leukemia virus-based vectors

Journal of Virology

Volumn 81, Issue 13, 2007, Pages 6973-6983

  Paar, Matthias ^a,b   Schwab, Sonja ^a   Rosenfellner, Doris ^a   Salmons, Brian ^c   Günzburg, Walter H ^a,b   Renner, Matthias ^c   Portsmouth, Daniel ^a,b  

^a UNIVERSITY OF VETERINARY MEDICINE   (Austria)

^b INSTITUTE FOR MICROELECTRONICS   (Austria)

^c Austrianova Biomanufacturing Company   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ENHANCED GREEN FLUORESCENT PROTEIN; GREEN FLUORESCENT PROTEIN; PLASMID VECTOR; RETROVIRUS VECTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER GENE THERAPY; CELL LINE; CELL TYPE; CONTROLLED STUDY; ENVELOPE GENE; EXPRESSION VECTOR; GENE EXPRESSION; GENOMIC INSTABILITY; HUMAN; HUMAN CELL; HUMAN TISSUE; LONG TERMINAL REPEAT; MALE; MOLONEY LEUKEMIA ONCOVIRUS; MOUSE; MURINE LEUKEMIA VIRUS; NONHUMAN; PRIORITY JOURNAL; SOLID TUMOR; TARGET CELL; TRANSGENE; VIRAL GENE THERAPY; VIRUS PARTICLE; VIRUS REPLICATION; VIRUS STRAIN;

ANIMALS; GENE EXPRESSION REGULATION, VIRAL; GENETIC VECTORS; GENOMIC INSTABILITY; HUMANS; MICE; MICE, NUDE; MOLONEY MURINE LEUKEMIA VIRUS; NIH 3T3 CELLS; SPECIES SPECIFICITY; TRANSGENES; VIRUS REPLICATION;

MOLONEY MURINE LEUKEMIA VIRUS; MURINAE; MURINE LEUKEMIA VIRUS; MUS MUSCULUS;

EID: 34250825853     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.02470-06     Document Type: Article

References (37)

1. Bachrach, E., M. Duch, M. Pelegrin, H. Dreja, F. S. Pedersen, and M. Piechaczyk. 2003. In vivo infection of mice by replication-competent MLV-based retroviral vectors. Methods Mol. Med. 76:343-352.
2. Bachrach, E., M. Pelegrin, M. Piechaczyk, F. S. Pedersen, and M. Duch. 2002. Efficient gene transfer into spleen cells of newborn mice by a replication-competent retroviral vector. Virology 293:328-334.
3. Celander, D., and W. A. Haseltine. 1984. Tissue-specific transcription preference as a determinant of cell tropism and leukaemogenic potential of murine retroviruses. Nature 312:159-162.
4. Coulombe, J., Y. Avis, and D. A. Gray. 1996. A replication-competent promoter-trap retrovirus. J. Virol. 70:6810-6815.
5. Dalba, C., D. Klatzmann, C. R. Logg, and N. Kasahara. 2005. Beyond oncolytic virotherapy: replication-competent retrovirus vectors for selective and stable transduction of tumors. Curr. Gene Ther. 5:655-667.
6. Dillon, P. J., J. Lenz, and C. A. Rosen. 1991. Construction of a replication-competent murine retrovirus vector expressing the human immunodeficiency virus type 1 Tat transactivator protein. J. Virol. 65:4490-4493.
7. Duch, M., M. L. Carrasco, T. Jespersen, B. D. Hansen, and F. S. Pedersen. 2004. Transgene stability for three replication-competent murine leukemia virus vectors. Gene 329:61-69.
8. Edelstein, M. L., M. R. Abedi, J. Wixon, and R. M. Edelstein. 2004. Gene therapy clinical trials worldwide 1989-2004 - an overview. J. Gene Med. 6:597-602.
9. Erlwein, O., C. J. Buchholz, and B. S. Schnierle. 2003. The proline-rich region of the ecotropic Moloney murine leukaemia virus envelope protein tolerates the insertion of the green fluorescent protein and allows the generation of replication-competent virus. J. Gen. Virol. 84:369-373.
10. Finger, C., Y. Sun, L. Sanz, L. Alvarez-Vallina, C. J. Buchholz, and K. Cichutek. 2005. Replicating retroviral vectors mediating continuous production and secretion of therapeutic gene products from cancer cells. Cancer Gene Ther. 12:464-474.
11. Graham, F. L., and A. J. van der Eb. 1973. A new technique for the assay of infectivity of human adenovirus 5 DNA. Virology 52:456-467.
12. Horton, R. M., H. D. Hunt, S. N. Ho, J. K. Pullen, and L. R. Pease. 1989. Engineering hybrid genes without the use of restriction enzymes: gene splicing by overlap extension. Gene 77:61-68.
13. Jespersen, T., M. Duch, M. L. Carrasco, S. Warming, and F. S. Pedersen. 1999. Expression of heterologous genes from an IRES translational cassette in replication competent murine leukemia virus vectors. Gene 239:227-235.
14. Klein, D., B. Bugl, W. H. Gunzburg, and B. Salmons. 2000. Accurate estimation of transduction efficiency necessitates a multiplex real-time PCR. Gene Ther. 7:458-463.
15. Klein, D., S. Indraccolo, K. von Rombs, A. Amadori, B. Salmons, and W. H. Gunzburg. 1997. Rapid identification of viable retrovirus-transduced cells using the green fluorescent protein as a marker. Gene Ther. 4:1256-1260.
16. Logg, C. R., and N. Kasahara. 2004. Retrovirus-mediated gene transfer to tumors: utilizing the replicative power of viruses to achieve highly efficient tumor transduction in vivo. Methods Mol. Biol. 246:499-525.
17. Logg, C. R., A. Logg, R. J. Matusik, B. H. Bochner, and N. Kasahara. 2002. Tissue-specific transcriptional targeting of a replication-competent retroviral vector. J. Virol. 76:12783-12791.
18. Logg, C. R., A. Logg, C. K. Tai, P. M. Cannon, and N. Kasahara. 2001. Genomic stability of murine leukemia viruses containing insertions at the Env-3′ untranslated region boundary. J. Virol. 75:6989-6998.
19. Logg, C. R., C. K. Tai, A. Logg, W. F. Anderson, and N. Kasahara. 2001. A uniquely stable replication-competent retrovirus vector achieves efficient gene delivery in vitro and in solid tumors. Hum. Gene Ther. 12:921-932.
20. Metzl, C., D. Mischek, B. Salmons, W. H. Gunzburg, M. Renner, and D. Portsmouth. 2006. Tissue- and tumor-specific targeting of murine leukemia virus-based replication-competent retroviral vectors. J. Virol. 80:7070-7078.
21. Miller, D. G., M. A. Adam, and A. D. Miller. 1990. Gene transfer by retrovirus vectors occurs only in cells that are actively replicating at the time of infection. Mol. Cell. Biol. 10:4239-4242.
22. Naldini, L., U. Blomer, F. H. Gage, D. Trono, and I. M. Verma. 1996. Efficient transfer, integration, and sustained long-term expression of the transgene in adult rat brains injected with a lentiviral vector. Proc. Natl. Acad. Sci. USA 93:11382-11388.
23. Nethe, M., B. Berkhout, and A. C. van der Kuyl. 2005. Retroviral superinfection resistance. Retrovirology 2:52.
24. Perron, M. J., M. Stremlau, B. Song, W. Ulm, R. C. Mulligan, and J. Sodroski. 2004. TRIM5alpha mediates the postentry block to N-tropic murine leukemia viruses in human cells. Proc. Natl. Acad. Sci. USA 101:11827- 11832.
25. Rainov, N. G., and H. Ren. 2003. Clinical trials with retrovirus mediated gene therapy - what have we learned? J. Neurooncol. 65:227-236.
26. Reik, W., H. Weiher, and R. Jaenisch. 1985. Replication-competent Moloney murine leukemia virus carrying a bacterial suppressor tRNA gene: selective cloning of proviral and flanking host sequences. Proc. Natl. Acad. Sci. USA 82:1141-1145.
27. Robson, N. D., and A. Telesnitsky. 2000. Selection of optimal polypurine tract region sequences during Moloney murine leukemia virus replication. J. Virol. 74:10293-10303.
28. Short, M. K., S. A. Okenquist, and J. Lenz. 1987. Correlation of leukemogenic potential of murine retroviruses with transcriptional tissue preference of the viral long terminal repeats. J. Virol. 61:1067-1072.
29. Sliva, K., O. Erlwein, A. Bittner, and B. S. Schnierle. 2004. Murine leukemia virus (MLV) replication monitored with fluorescent proteins. Virol. J. 1:14.
30. Solly, S. K., S. Trajcevski, C. Frisen, G. W. Holzer, E. Nelson, B. Clerc, E. Abordo-Adesida, M. Castro, P. Lowenstein, and D. Klatzmann. 2003. Replicative retroviral vectors for cancer gene therapy. Cancer Gene Ther. 10: 30-39.
31. Stuhlmann, H., R. Jaenisch, and R. C. Mulligan. 1989. Construction and properties of replication-competent murine retroviral vectors encoding methotrexate resistance. Mol. Cell. Biol. 9:100-108.
32. Sun, Y., C. Finger, L. Alvarez-Vallina, K. Cichutek, and C. J. Buchholz. 2005. Chronic gene delivery of interferon-inducible protein 10 through replication-competent retrovirus vectors suppresses tumor growth. Cancer Gene Ther. 12:900-912.
33. Tai, C. K., C. R. Logg, J. M. Park, W. F. Anderson, M. F. Press, and N. Kasahara. 2003. Antibody-mediated targeting of replication-competent retroviral vectors. Hum. Gene Ther. 14:789-802.
34. Tai, C. K., W. J. Wang, T. C. Chen, and N. Kasahara. 2005. Single-shot, multicycle suicide gene therapy by replication-competent retrovirus vectors achieves long-term survival benefit in experimental glioma. Mol. Ther. 12: 842-851.
35. Wang, W., C. K. Tai, A. D. Kershaw, S. K. Solly, D. Klatzmann, N. Kasahara, and T. C. Chen. 2006. Use of replication-competent retroviral vectors in an immunocompetent intracranial glioma model. Neurosurg. Focus 20:E25.
36. Wang, W. J., C. K. Tai, N. Kasahara, and T. C. Chen. 2003. Highly efficient and tumor-restricted gene transfer to malignant gliomas by replication-competent retroviral vectors. Hum. Gene Ther. 14:117-127.
37. Yap, M. W., S. Nisole, C. Lynch, and J. P. Stoye. 2004. Trim5alpha protein restricts both HIV-1 and murine leukemia virus. Proc. Natl. Acad. Sci. USA 101:10786-10791.